Abstract
O-(1′-[18F]fluoropropan-2′-yl)-l-tyrosine (1-[18F]FPT) was synthesized using the Ni(II)-(S)-[N-2-(N′-benzylprolyl)amino]benzophenone-S-tyrosine based precursor. The precursor was synthesized through a two-step process starting from RS-tyrosine, (S)BPB and Ni(II) chloride hexahydrate. The precursor was [18F]radiofluorinated, followed by hydrolysis with 2 M HCl to obtain 1-[18F]FPT. The reaction mixture was purified using neutral alumina column. Radiolabeling efficiency and radiochemical yield (after purification and decay uncorrected) was 60 and 5% respectively. Total time for synthesis was 70 min. This synthesis procedure for (1-[18F]FPT) gave a radiochemical purity of 98% with enantiomeric purity of 93%, and can easily be adapted in any standard 2-[18F]FDG synthesis module.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10967-017-5416-6/MediaObjects/10967_2017_5416_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10967-017-5416-6/MediaObjects/10967_2017_5416_Fig2_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10967-017-5416-6/MediaObjects/10967_2017_5416_Fig3_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10967-017-5416-6/MediaObjects/10967_2017_5416_Fig4_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10967-017-5416-6/MediaObjects/10967_2017_5416_Fig5_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10967-017-5416-6/MediaObjects/10967_2017_5416_Fig6_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10967-017-5416-6/MediaObjects/10967_2017_5416_Fig7_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10967-017-5416-6/MediaObjects/10967_2017_5416_Fig8_HTML.gif)
Similar content being viewed by others
References
Hoh CK (2007) Clinical use of FDG PET. Nucl Med Biol 34:737–742
Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J (1996) Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23:1641–1674
Shreve PD, Anzai Y, Wahl RL (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19:61–77
Laverman P, Boerman OC, Corsten FHM, Oyen WJG (2002) Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med 29:681–690
Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, Molls M, Stocklin G, Schwaiger M (2000) O-(2-[18F]fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 27:542–549
Shoup TM, Olson J, Hoffman JM, Votaw J, Eshima D, Eshima L, Camp VM, Stabin M, Votaw D, Goodman MM (1999) Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med 40:331–338
Wester WJ, Herz M, Senekowitsch-Schmidtke R, Schwaiger M, Stocklin G, Hamacher K (1999) Synthesis and radiopharmacology of O-(2-[18F] fluoroethyl)-l-tyrosine for tumor imaging. Nucl Med Biol 26:259–265
Kubota K, Ishiwata K, Kubota R, Yamada S, Takahashi J, Abe Y, Fukuda H, Ido T (1996) Feasility of fluoroine-18-fluorophenyl alanine for tumor imaging in comparisone to carbon-11-methionine. J Nucl Med 37:320–325
Hustinx R, Lemaire C, JerusalemG Moreau P, Cataldo D, Duysinx B, Aerts J, Fassotte MF, Foidart J, Luxen A (2003) Whole-body tumor imaging using PET and 2-18F-Fluoro-l-tyrosine: preliminary evaluation and comparison with 18F-FDG. J Nucl Med 44:533–539
Shikano N, Kawai D, Flores LG, Nishii R, Kubota N, Ishikawa N, Kubodera A (2003) An artificial amino acid, 4-Iodo-l-meta-tyrosine: biodistribution and excretion via kidney. J Nucl Med 44:625–631
Inoue T, Tomiyoshi K, Higuichi T, Ahmed K, Sarwar M, Aoyagi K, Amano S, Alyafei S, Zhang H, Endo K (1998) Biodistribution studies on L-3-[Fluorine-18]Fluoro-α-Methyl tyrosine: a potential tumor-detecting agent. J Nucl Med 39:663–667
Langen KJ, Muhlensiepen H, Holschbach M, Hautzel H, Jansen P, Coenen HH (2000) Transport mechanism of 3-[123I] Iodo-α-methyl-l-tyrosine in comparison with methyl-[3H]-l-methionine. J Nucl Med 41:1250–1255
Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, Stocklin G (1999) Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-l-tyrosinefor tumor imaging. J Nucl Med 40:205–212
Heiss P, Mayer S, Herz M, Wester HJ, Schwaiger M, Senekowitsch-Schmidtke R (1999) Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-l-tyrosine in vitro and in vivo. J Nucl Med 40:1367–1373
Rau RC, Weber WA, Wester HJ, Herz M, Becker I, Kruger A, Schwaiger M, Senekowitsch-Schmidtke R (2002) O-(2-[18F]fluoroethyl)-Ltyrosine(FET): a tracer for differentiation of tumour from inflammationin murine lymph nodes. Eur J Nucl Med 29:1039–1046
Kaim AH, Weber B, Kurrer MQ, Westera G, Schweitzer A, Gottschalk J, von Schulthess GK, Buck A (2002) 18F-FDG and 18F-FETuptake in experimental soft tissue infection. Eur J Nucl Med 29: 648–654
Tang GH, Wang MF, Tang XL, Luo L, Gan MQ (2003) Pharmacokineticsand radiation dosimetry estimation of O-(2-18F-fluoroethyl)-l-tyrosineas oncologic PET tracer. Appl Radiat Isot 58:219–225
Moon BS, Kim SW, Lee TS, Ahn SH, Lee KC, An GI, Yang SD, Chi DY, Choi CW, Lim SM, Chun KS (2005) Synthesis of O-(3-[18F]Fluoropropyl)-l-tyrosine (L-[18F]FPT) and its biological evaluation in 9L tumor bearing Rat. Bull Korean Chem Soc 26:91–96
Lee KC, Lee SY, Choe YS, Chi DY (2004) Metabolic stability of [18F]fluoroalkylbiphenyls. Bull Korean Chem Soc 25:1225–1230
Tang G, Wang M, Tang X, Luo L, Gan M (2003) Synthesis and evaluation of O-(3-[18F]Fluoropropyl)-l-tyrosine as an oncologic PET tracer. Nucl Med Biol 30:733–739
Tang G, Tang X, Wang M, Luo L, Gan M (2003) Fully automated synthesis of O-(3-[18F]fluoropropyl)-l-tyrosine by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Appl Radiat Isot 58:685–689
Tang G, Tang X, Wang M, Luo L, Gan M (2004) Radiation dosimetry of O-(3-[18F]fluoropropyl)-l-tyrosine as oncologic PET tracer based on the mice distribution data. Appl Radiat Isot 60:27–32
Krasikova RN, Kuznetsova OF, Fedorova OF, Maleev VI, Saveleva TF, Belokon YN (2008) No carrier added synthesis of O-(2′-[18F]fluoroethyl)-l-tyrosine via a novel type of chiral enantiomerically pure precursor, Ni(II) complex of a (S)-tyrosine Schiff base. Bioorg Med Chem 16:4994–5003
Kuntzsch M, Lamparter D, Brüggener N, Müller M, KienzleGJ Reischl G (2014) Development and successful validation of simple and fast TLC spot tests for determination of Kryptofix® 2.2.2 and Tetrabutylammonium in 18F-labeled radiopharmaceuticals. Pharmaceuticals 336:621–633
Acknowledgements
Our sincere thanks to all scientists and technologists in the Medical Cyclotron Facility, BRIT/BARC, Mumbai for providing [F-18]radioactivity as per our requirements for our experiments. Our special thanks to Dr. Swain, Analytical Chemistry Division, BARC for providing ICP-MS analysis report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lakshminarayanan, N., Banerjee, S. & Rajan, M.G.R. Synthesis of O-(1′-[18F]fluoropropan-2′-yl)-l-tyrosine (1-[18F]FPT) via Ni(II) complex of (S) tyrosine schiff’s base precursor. J Radioanal Nucl Chem 314, 483–490 (2017). https://doi.org/10.1007/s10967-017-5416-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-017-5416-6